COMP <GO>
KNSA vs LLY // EV/EBITDA & P/E VALUATION
Kiniksa Pharmaceuticals International plc Class A (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: KNSA 4
— LLY 10
▲ EV/EBITDA & P/E VALUATION LEADER: LLY
LAST: $92.24 (-5.45%) • MKT CAP: $7.67B
valuation
95.0x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 83.64% | +4.86 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 32.36% | -22.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 36.4x | +58.58 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 2.30% | -0.52 | LLY | /fcf-yield <GO> |
| Operating Margin | 11.40% | 40.21% | -28.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 31.90% | -23.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 45.51% | +14.59 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 9.29 | +15.16 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.77% | +0.53 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 77.9 | -14.90 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.51 | +0.60 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 26.3x | +82.85 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.67B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | LLY REV | KNSA GROSS % | LLY GROSS % | KNSA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $65.18B | 88.5% | 83.0% | $136.4M | $16.81B |
| FY 2024 | $423.2M | $45.04B | 85.6% | 81.3% | $25.4M | $8.82B |
| FY 2023 | $270.3M | $34.12B | 44.0% | 79.3% | $1.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
LLY // BETA 0.51